Changes In Cyclic AMP Research Articles

Metabolic and hormonal changes in moderate and intense long-term running exercises.

The changes in selected muscle and blood metabolites - blood catecholamines, cyclic AMP, glucagon, growth hormone, insulin, and C-peptide--were measured in five male long-distance runners after moderate 90 min (4.3 min/km) and intense 45 min (3.3 min/km) of continuous running exercises. After the 45-min exercise, the mean concentrations of blood lactate and glucose were 2.8 and 8.8 mmol/l, respectively, and the muscle glycogen concentration had decreased by 31%. No changes could be found after the 90 min of running. The increase in blood glycerol concentration was greater after the 45-min exercise (5.8-fold) than after the 90-min exercise (3.9-fold), although the serum free fatty acid concentration increased significantly only during the 90-min exercise (1.6-fold). Plasma noradrenaline increases were 2.7-fold and 7.9-fold during the 90- and 45-min exercises, respectively, whereas the plasma adrenaline concentration was significantly elevated only after the 45-min exercise (4.7-fold). The respective changes of plasma cyclic AMP were 2.5- and 2.7-fold, and the increase in the concentration of plasma growth hormone was 5.8-fold after the 45-min exercise. The plasma insulin level decreased during the 90-min exercise, but was elevated after the 45-min exercise. The increase was greater than could be expected on the basis of the plasma C-peptide concentration. It is concluded that the hormonal and metabolic changes during submaximal long-term exercises are highly dependent on the intensity of exercise, even when the intensity of exercise is below the level of the anaerobic threshold.(ABSTRACT TRUNCATED AT 250 WORDS)

Cyclic GMP increases photocurrent and light sensitivity of retinal cones.

Like retinal rods, cone photoreceptors contain cyclic GMP and light-activated phosphodiesterase. The cGMP phosphodiesterase cascade is thought to mediate phototransduction in rods. Biochemical assays of nucleotide content in cone-dominant retinas, however, have failed to demonstrate light-induced changes in cGMP. Changes in cyclic AMP following light exposure have been reported, leading to the suggestion that in cone phototransduction cAMP assumes a role analogous to that played by cGMP in rods. Cyclic GMP introduced from tight-seal pipettes into isolated cones of the larval tiger salamander, Ambystoma tigrinum, rapidly increases light-modulated membrane current more than 10-fold. In cones, as in rods, cGMP also causes an approximately 10-fold increase in photocurrent duration and a 5- to 10-fold increase in light-sensitivity. Cyclic AMP has no effect on cone photocurrents under the same conditions. Because cGMP has similar effects on photocurrent magnitude and kinetics in both rods and cones, we conclude that cGMP plays corresponding roles in transduction in both vertebrate photoreceptor classes.

ChemInform Abstract: A NEW GENERATION OF PHOSPHODIESTERASE INHIBITORS: MULTIPLE MOLECULAR FORMS OF PHOSPHODIESTERASE AND THE POTENTIAL FOR DRUG SELECTIVITY

With several notable exceptions, interest in the area of multiple molecular forms of phosphodiesterase remained relatively dormant during the decade following Thompson's discovery of more than one phosphodiesterase in brain in 1971. Within the last several years, however, over 20 novel agents have been identified that exert selective inhibitory effects on the various molecular forms of phosphodiesterase present within different cells. In addition, several studies have documented that such agents can produce discrete changes in cyclic AMP and cyclic GMP, an action that is not shared by first generation phosphodiesterase inhibitors such as theophylline. The purpose of this Perspective is to provide some clarity to this rapidly evolving area of selective phosphodiesterase inhibitors. Thus, we have attempted to characterize the different forms of phosphodiesterase present in various tissues and cells according to their kinetic properties, substrate specificity, etc. and also to characterize those major classes of agents that have been shown to inhibit phosphodiesterase activity, whether selectively or nonselectively. In addition, we have described several therapeutic areas wherein selective phosphodiesterase inhibitors might prove efficacious, paying particular attention to those areas in which selective phosphodiesterase inhibitors have already been shown to exert beneficial effects, namely, stimulation of myocardial contractility, inhibition of mediator release, and inhibition of platelet aggregation. Although focusing on these three areas, it is obvious that the potential therapeutic utility of selective phosphodiesterase inhibitors could conceivably extend to several other areas in which modulation of cyclic nucleotides can have desirable effects, including cancer chemotherapy, analgesia, the treatment of depression, Parkinson's disease, and learning and memory disorders. For example, the selective type III phosphodiesterase inhibitor rolipram has been shown to antagonize reserpine-induced hypothermia and also to potentiate yohimbine lethality, two tests that are indicative of antidepressant activity. In addition, microinjection of the selective PDE III inhibitor Ro 20-1724 into the rat brain stem has been shown to produce analgesia.(ABSTRACT TRUNCATED AT 400 WORDS)

Influence of thiol groups, calcium, and glucose metabolism on cholinergic-induced insulin release and on methylscopolamine binding to muscarinic receptors in pancreatic islets of the rat

Short-term regulation of [3H]methylscopolamine binding to muscarinic receptors and acetylcholine-induced stimulation of insulin release was investigated in pancreatic islets of the rat. Binding of methylscopolamine was reversible; 47% of label was displaced 10 min and 70% 30 min after addition of unlabelled substance. 0.1 mM chloromercuribenzoic acid, when present during binding incubations, inhibited binding by 54%, whereas acetylcholine-induced insulin release was unaffected by the presence of the thiol reactant. Pre-incubation for 60 min in a calcium-deprived medium or in the presence of 50 microM trifluoroperazine likewise inhibited binding. Pre-incubation with 1.0 mM 3-isobutyl-l-methylxanthine or 16.7 M glucose failed to influence subsequent binding although acetylcholine-induced insulin release was 4-fold enhanced by priming with glucose. We conclude that 1) binding to muscarinic receptors is influenced by thiol interaction, 2) short-term alterations in calcium fluxes influence binding, whereas short-term changes in cyclic AMP (cAMP) or glucose metabolism do not, 3) a priming effect of glucose on insulin secretion is not mediated by changes in receptor binding.

Regulation of adenosine 3′:5′-monophosphate-dependent protein kinase in cerebral cortex

Alterations in the cyclic AMP-dependent protein kinase activity ratio in response to putative neurotransmitters and other cyclic AMP-elevating agents in intact cerebral cortical slices and Krebs-Ringer particulate preparations from cerebral cortex were examined. Both norepinephrine (30 μM) and forskolin (20 μM) produced a time-dependent increase in intracellular levels of cyclic AMP in cerebral cortical slices which was paralleled by an increase in both cyclic AMP and the protein kinase activity ratio. The increases were maximal at 5 min. and remained elevated for at least 15 min. Forskolin, norepinephrine, adenosine and isoproterenol produced a concentration-dependent increase in both cyclic AMP and the protein kinase activity ratio, however, the degree of increase observed was dissimilar. Thus, a 5-fold change in intracellular cyclic AMP resulted in only a 2-fold increase in the activity ratio. Of the agents examined, forskolin produced the most marked change in the activity ratio (from 0.23 to 0.78 at 100 μM) while isoproterenol at 100 μM produced only a 50% increase in the activity ratio. The half-time for the decline in forskolin elicited elevations of either the activity ratio or cyclic AMP was about 4–6 min. In the presence of the phosphodiesterase inhibitor, Ro 20-1724, both were significantly prolonged being 60–70% of the maximum observed immediately after forskolin stimulation, at 15 min. Potentiation of forskolin elicited increases in the activity ratio by Ro 20-1724 were also observed but the increase in the activity ratio was maximal at 7.5 min. while cyclic AMP accumulations continued to rise during the entire 15 min. incubation. Particulate preparations from cerebral cortex were found to contain a cyclic AMP-dependent protein kinase which could be activated 2 to 3-fold with either forskolin, norepinephrine, or adenosine. Unlike the intact brain slice the changes in protein kinase activity ratio and intracellular levels of cyclic AMP in cell-free particulate preparations were similar in both time and degree.

Rhythmic cyclic AMP changes in [formula omitted] cells synchronized by temperature and light cycles in chemostat culture

Division in chemostat cultures of Chlamydomonas reinhardi was synchronized by daily cycles of both temperature and light. In response to 8 h cool (20 °C) — dim light / 16 h warm (28 °C) — bright light cycles and continuous dilution that removed half the cells daily, the cells replicated nuclear DNA late in the warm-bright phase; released an average of two daughter zoospores early in the warm-bright phase of the next cycle. In these synchronized green algal cultures all ATP and most cAMP were intracellular; most cGMP (approximately 91%) was extracellular. Early in the warm-bright phase ATP doubled after which cAMP level fell 25%. During DNA replication cAMP level doubled, rising to a modest peak reached as replication ended.

A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.

With several notable exceptions, interest in the area of multiple molecular forms of phosphodiesterase remained relatively dormant during the decade following Thompson's discovery of more than one phosphodiesterase in brain in 1971. Within the last several years, however, over 20 novel agents have been identified that exert selective inhibitory effects on the various molecular forms of phosphodiesterase present within different cells. In addition, several studies have documented that such agents can produce discrete changes in cyclic AMP and cyclic GMP, an action that is not shared by "first generation" phosphodiesterase inhibitors such as theophylline. The purpose of this Perspective is to provide some clarity to this rapidly evolving area of selective phosphodiesterase inhibitors. Thus, we have attempted to characterize the different forms of phosphodiesterase present in various tissues and cells according to their kinetic properties, substrate specificity, etc. and also to characterize those major classes of agents that have been shown to inhibit phosphodiesterase activity, whether selectively or nonselectively. In addition, we have described several therapeutic areas wherein selective phosphodiesterase inhibitors might prove efficacious, paying particular attention to those areas in which selective phosphodiesterase inhibitors have already been shown to exert beneficial effects, namely, stimulation of myocardial contractility, inhibition of mediator release, and inhibition of platelet aggregation. Although focusing on these three areas, it is obvious that the potential therapeutic utility of selective phosphodiesterase inhibitors could conceivably extend to several other areas in which modulation of cyclic nucleotides can have desirable effects, including cancer chemotherapy, analgesia, the treatment of depression, Parkinson's disease, and learning and memory disorders. For example, the selective type III phosphodiesterase inhibitor rolipram has been shown to antagonize reserpine-induced hypothermia and also to potentiate yohimbine lethality, two tests that are indicative of antidepressant activity. In addition, microinjection of the selective PDE III inhibitor Ro 20-1724 into the rat brain stem has been shown to produce analgesia.(ABSTRACT TRUNCATED AT 400 WORDS)

Benzodiazepines inhibit human platelet activation: Comparison of the mechanism of antiplatelet actions of flurazepam and diazepam

These studies were undertaken to examine the effects and the mechanism of action of flurazepam and diazepam on human platelet activation. One minute preincubation with flurazepam (3–300 uM) or diazepam (3–300 uM) inhibited platelet aggregation, serotonin secretion and prostaglandin synthesis induced by ADP (1–5 uM), epinephrine (1–5 uM), and arachidonic acid (600–1000 uM). However, 357% higher concentration of diazepam (265 uM) as compared to flurazepam (58 uM), was required to inhibit arachidonic acid induced production of malondialdehyde (MDA) by 50%. In addition, flurazepam and not diazepam inhibited the release of arachidonic acid from platelet phospholipids in a concentration dependent manner. In other experiments flurazepam but not diazepam also blocked aggregation and secretion induced by U46619 (2 uM), a stable analog of prostaglandin H2. Platelet aggregation and serotonin secretion induced by collagen (40–300 ug/ml) was inhibited by flurazepam with an IC-50 of 153 uM and 136 uM respectively, whereas higher than 300 uM diazepam was required to inhibit collagen-induced aggregation and secretion by 50%. Flurazepam and diazepam both exhibited their most potent antiplatelet effects against phospholipase C-induced aggregation which is mediated by prostaglandin-independent mechanisms. Only 15 uM and 11 uM flurazepam and 31 uM and 27 uM diazepam were needed to inhibit PLC-induced aggregation and secretion of serotonin by 50% respectively. Effects of these benzodiazepines on platelet cyclic AMP and cyclic GMP were also examined. Neither flurazepam nor diazepam caused any significant change in cyclic AMP or cyclic GMP levels in platelets.. These findings suggest that: (a) flurazepam, as compared to diazepam, is 106% - 357% more effective in inhibiting platelet aggregation and serotonin secretion induced by arachidonic acid , collagen and phospholipase C; (b) flurazepam inhibits platelet activation by inhibiting the release of arachidonic acid, its conversion into prostaglandins and by blocking the action of prostaglandins on platelets; (c) diazepam does not inhibit thrombin-induced release of arachidonic acid, conversion of exogenously added arachidonic acid into MDA, or the action of prostaglandins; (d) both flurazepam and diazepam inhibit PLC-mediated activation of platelets; and (e) neither diazepam nor flurazepam achieve their antiplatelet actions by affecting platelet cyclic nucleotide levels.

Role of cyclic AMP in the induction of histamine secretion from mast cells

Immunological activation of rat peritoneal mast cells induced a transient elevation in the intracellular concentration of cyclic AMP. Enhancement or suppression of this rise by appropriate adenosine analogues produced parallel changes in histamine secretion. However, pharmacological activation of the cell with a number of diverse ligands induced histamine release without any accompanying changes in cyclic AMP. Moreover, this release was modulated by adenosine analogues in identical fashion to IGE-directed ligands but again without affecting cyclic AMP. On the basis of these results, the possible role of cyclic AMP in the induction of histamine secretion is critically considered.

Changes in cyclic AMP and cyclic GMP levels in the contraction-relaxation cycle of isolated smooth muscle cells from guinea-pig taenia caeci.

The present study was undertaken to investigate the role of cyclic AMP and cyclic GMP in the regulation of the contraction-relaxation cycle in isolated smooth muscle cells from guinea pig taenia caeci. The contraction of isolated smooth muscle cells induced by both caffeine (4 X 10(-3) M) and carbachol (10(-4) M) consisted of an initial activation phase and a following spontaneous relaxation phase. Isoproterenol (10(-4) M) inhibited the carbachol-induced contraction and raised intracellular cyclic AMP level of isolated smooth muscle cells. Both the inhibition of the carbachol-induced contraction and the rise in cyclic AMP level elicited by isoproterenol were blocked by propranolol (10(-4) M). Caffeine increased intracellular cyclic AMP level significantly and contracted isolated smooth muscle cells. Caffeine and carbachol contracted isolated smooth muscle cells and increased intracellular cyclic GMP level. Cyclic GMP was significantly increased in spontaneous relaxation phase. The data suggest that beta-adrenergic inhibitory effect on cholinergic excitation in the mammalian isolated smooth muscle cells is mediated by the change in intracellular cyclic AMP level and that cyclic GMP related to the relaxation in these single cells. Thus, it appears that caffeine-induced contraction might be due to the stimulation of Ca2+-induced Ca2+ release by cyclic AMP.

Pharmacology and receptor binding of atrial natriuretic factor in vascular smooth muscle.

Characterization of the vascular pharmacology and receptor binding of atrial natriuretic factor (ANF) has been achieved utilizing a synthetic peptide which contains the sequence and biological activity of ANF. The synthetic ANF (sANF) relaxes aortic segments contracted by agonists or by low (15 to 20 mM) but not high (greater than or equal to 40 mM) concentrations of K+. The relaxation to sANF is well maintained, reversible, independent of the vascular endothelium and correlated with increases in cyclic GMP (with no change in cyclic AMP). Plasma membranes prepared from rabbit aorta and kidney possess high affinity (Kd = 100 pM) specific binding sites for sANF. An excellent correlation exists between the receptor binding and pharmacology for several synthetic analogs of ANF. The presence of these receptors appears consistent with the activation of particulate (but not soluble) guanylate cyclase by sANF. sANF does exhibit a profound regional vasodilator selectivity which can be explained, in part, by changes in receptor density.

Fructose 2,6-biphosphate, sugar phosphates and adenine nucleotides in the regulation of glucose metabolism in the lactating rat mammary gland

Fructose 2,6-bisphosphate is present in the rat mammary gland, rising from a value of 1.4 nmol/g in pregnancy to 4.3 nmol/g tissue at 14 days lactation; the equivalent values calculated/ml intracellular water are 5.2 and 11.6 nmol, respectively. The tissue content of fructose 6-phosphate, fructose 1,6-bisphosphate, ATP and phosphoenolpyruvate remain relatively constant in the transition from pregnancy to the height of lactation. The changes in AMP, cyclic AMP, and citrate content of the mammary gland during lactation are such as to promote an increase in frutose 2,6-bisphosphate formation and flux through phosphofructokinase.

Capacitative pulsed electric stimulation of bone cells. Induction of cyclic-AMP changes and DNA synthesis

Pulsed electric stimulation, coupled capacitively to bone cells isolated from rat embryo calvaria, caused changes in the intracellular level of cyclic AMP and enhanced DNA synthesis. The capacitive method of electrical stimulation was characterized in terms of displacement currents (0.7–4.0 A) and voltages (10–54 V/cm) prevailing in the stimulation chamber. Changes, both in cyclic AMP and in incorporation of [ 3H]thymidine into DNA, were correlated with the strength of the applied electric field. Unlike the mechanical stimulation of bone cells, the electrical stimulus was not mediated by de novo synthesis of prostaglandins. The findings suggest that cyclic-AMP changes, induced by the capacitive electrical stimulation of bone cells, trigger DNA synthesis.

Urinary adenosine cyclic 3',5'-monophosphate in idiopathic calcium stone-formers: response to an oral calcium load.

Idiopathic calcium stone-formers with hypercalciuria during fasting have significantly lower urinary cyclic AMP levels (nmol/dl of glomerular filtrate) than fasting normocalciuric stone-formers. Female subjects, including both normal subjects and idiopathic calcium stone-formers, have higher urinary cyclic AMP levels than their male counterparts, and this difference is significant when urinary cyclic AMP is expressed in the units mumol/g of creatinine. Expressing urinary cyclic AMP in nmol/dl of glomerular filtrate reduces this difference but does not abolish it. Thus, in comparing urinary cyclic AMP levels in various subgroups of the calcium stone-formers and in normal subjects, both sex differences and the units of urinary cyclic AMP expression must be taken into consideration. The magnitude of the change in urinary cyclic AMP in response to an oral calcium load appears to depend on the antecedent urinary cyclic AMP excretion rate, whereby those individuals (either normal subjects or calcium stone-formers) having the highest urinary cyclic AMP levels demonstrate the greatest fall in urinary cyclic AMP after a calcium load.

Mechanism of regulation of amylase release by alpha- and beta-adrenergic agonists in rat parotid tissue.

The effect of forskolin and isobutyl-methylxanthine on amylase release and cyclic AMP accumulation by alpha- and beta-adrenergic agonists was studied in rat parotid slices. A small increase in cyclic AMP by beta-adrenergic agonists was sufficient for maximum stimulation of amylase release (Yoshimura et al., 1982a), but a similar increase in cyclic AMP by forskolin did not stimulate the maximum amount of amylase release. The amount of amylase release and cyclic AMP changed in parallel when lower doses of isobutyl-methylxanthine were used, but higher doses of isobutyl-methylxanthine further increased cyclic AMP without causing a significant increase in amylase release. Amylase release stimulated to its maximum by isobutyl-methylxanthine was much lower than that by isoproterenol. These results suggest that cyclic AMP is not the only chemical correlate for the activation of amylase release by beta-adrenergic agonists. The effect of phenylephrine and methoxamine on amylase release was augmented by either forskolin or isobutyl-methylxanthine, but the effect of methacholine was not. Phenylephrine increased the cyclic AMP concentration under the same conditions, but methoxamine did not. The inhibition of the effect of phenylephrine plus forskolin on cyclic AMP accumulation by propranolol was almost complete and stereospecific, but the inhibition of their effects on amylase release was incomplete and not stereospecific. Synergism of amylase release was observed in the effect between methoxamine and dibutyryl-cyclic AMP. These results suggest that the augmentation of the effect of alpha-adrenergic agonists on amylase release by forskolin or isobutyl-methylxanthine cannot be explained only on changes in cyclic AMP and that some other factor in collaboration with cyclic AMP may participate in the regulation of amylase release by alpha-adrenergic agonists.

Changes in serum cyclic nucleotide concentration during open-heart surgery.

Changes in serum cyclic AMP and GMP concentrations were studied in 14 patients undergoing open-heart surgery with cold cardioplegia. Blood samples were taken on total bypass from the radial artery and from the coronary sinus before aortic cross-clamping and 1 and 9 min after declamping. The samples were analyzed for cyclic nucleotides. The cAMP levels showed no pronounced change in the arterial samples, but were significantly increased in the coronary sinus samples after declamping of the aorta. The cGMP values showed the same trend of change in the arterial and the coronary sinus samples, viz. significant fall after aortic release, and after 9 min an increase. The cAMP/cGMP ratio after clamp removal showed pronounced increase in the first minute and some reduction at 9 min. All the changes were statistically significant. Beating recommenced spontaneously in seven hearts. The cAMP levels were lower in this group than in the patients without spontaneous recovery. The outset cGMP levels and the cAMP/cGMP ratio were higher in the latter group. Absence of increase in the cGMP level may be due to effectiveness of cardioplegia in reducing the energy requirements of the ischemic myocardium. The study indicates that hearts without spontaneous recovery of beating react more sensitively to hypoxia and have to use up more of their energy resources for restoration of function.

Cyclic AMP changes in guinea pig mammary gland and milk.

Cyclic AMP was measured in guinea pig mammary gland biopsies from midpregnancy through lactation and in daily milk samples throughout lactation. The results indicate that mammary gland cAMP levels rise sharply in late pregnancy to a prepartum peak and then drop abruptly at partus. This is similar to the pattern observed by others in rat and mouse although the guinea pig does not undergo a prepartum progesterone withdrawal. In animals with a 3-wk lactation period, milk cAMP concentration decreases approximately 40% between days 10 and 20, whereas the mammary gland level increases 22% per unit wet tissue weight. Although milk concentrations of lactose and cAMP are weakly correlated, a strong correlation exists between the total collected daily outputs of these two substances. The results suggest that, as lactation proceeds, mammary gland cAMP levels gradually increase, whereas milk cAMP levels decrease. Concurrently, lactose output decreases as lactation proceeds. These observations are consistent with first, a milk secretory route for regulating mammary gland cAMP levels (in addition to synthesis and hydrolysis), and second, an inhibitory action of cAMP on lactose synthesis.

Studies of prostatic cytosol protein kinases of the aging ACI rat

Changes in prostatic cytosolic cyclic AMP (cAMP)-dependent and -independent protein kinases associated with aging in ACI rats were determined. A decrease in prostatic weight and tissue protein content (but not DNA) with age was noted. The cytosolic cAMP-dependent protein kinase was present predominantly as the type II isozyme. Total content of this enzyme per prostate declined by 37% in 12-month-old rats but remained relatively stable thereafer. However, the activity ratio (+cAMP/−cAMP) increased with aging, indicating an elevation in the amount of the holoenzyme or a decrease in the amount of the free catalytic subunit. Concomitantly the specific activity (activity/unit protein in the cytosol) of this enzyme was found to be increased; this is most likely due to the loss of bulk proteins in the cytosol, and may indicate a slower loss of this enzyme protein in relation to other cytosolic proteins. By comparison, the cAMP-independent protein kinase demonstrated a marked and progressive decline in amount as well as in specific activity with aging, e.g. 80–90% decline at 12 months of age. The above changes in these enzymes did not appear to be due to low circulating androgen in the animals, since they were not reversed on administration of 3.0 mg of testosterone propionate per rat daily for four consecutive days. It is therefore suggested that the above-described changes in prostatic cytosolic protein kinases are primarily associated with cellular senescence in this organ.

Neuropeptides modulate the beta-adrenergic response of purified astrocytes in vitro.

Neuropeptides may have functions in the central nervous system (CNS) other than altering neuronal excitability. For example, they may act as regulators of brain metabolism by affecting glycogenolysis. Since it has been suggested that glial cells might provide metabolic support for neuronal activity, they may well be one of the targets for neuropeptide regulation of metabolism. Consistent with this view are reports that peptide-containing nerve terminals have been seen apposed to astrocytes, but it is also quite possible that peptides could act at sites lacking morphological specialization. Primary cultures containing CNS glial cells have been shown to respond to beta-adrenergic agonists with an increase in cyclic AMP and, as a result, with an increase in glycogenolysis and have also been shown to respond to a variety of peptides with changes in cyclic AMP. In the study reported here, we have examined the effects of several peptides on relatively pure cultures of rat astrocytes. We demonstrate that the increase in intracellular cyclic AMP induced by noradrenaline is markedly enhanced by somatostatin and substance P and is inhibited by enkephalin, even though these peptides on their own have little or no effect on the basal levels of cyclic AMP. Vasoactive intestinal peptide (VIP) on the other hand increases cyclic AMP in the absence of noradrenaline. These results suggest that neuropeptides influence glial cells as well as neurones in the CNS and, in the case of somatostatin and substance P, provide further examples of neuropeptides modulating the response to another chemical signal without having a detectable action on their own.

The relationship between cyclic amp changes and histamine release from basophil-rich human leucocytes

Histamine release and changes in cyclic AMP levels induced by a variety of stimuli have been measured in isolated human leucocytes from a patient with 40–70% basophilia. Adenosine and sodium fluoride induced early monophasic rises in cyclic AMP which peaked at 1 min, but they did not release histamine. 2′,5′-Dideoxyadenosine (DDA) caused a transient fall in cyclic AMP levels. AntiIgE, polylysine and calcium ionophore A23187 induced a slow release of histamine commencing 2–5 min after addition of secretagogue. With polylysine and A23187, release was still proceeding 45 min after challenge. In contrast, the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (f-metleu-phe) induced a rapid secretion of histamine which was complete within 2 min. Anti-IgE induced a rapid monophasic rise in cyclic AMP which reached a maximum at 45 sec and was inhibited by pretreatment with DDA. Cyclic AMP rises induced by polylysine and f-met-leu-phe were kinetically similar but smaller in magnitude. A23187 caused a later rise in cyclic AMP which peaked 3 min after challenge. A high concentration (50μM) of compound 48/80 induced a slow cytotoxic release of histamine which was not accompanied by changes in cyclic AMP levels. The inconsistent quantitative and kinetic relationships of histamine release and cyclic AMP production suggest that changes in cyclic AMP levels may not play a key role in the biochemical events leading to mediator secretion from human basophil leucocytes.